< 生产厂家价格 >

顺式乌头酸酐

顺式乌头酸酐用途

生化研究。

点击显示

顺式乌头酸酐名称

[ CAS 号 ]:
6318-55-4

[ 中文名 ]:
顺式乌头酸酐

[ 英文名 ]:
(2,5-Dioxotetrahydro-3-furanyl)acetic acid

[中文别名 ]:

[英文别名 ]:

(2,5-Dioxo-2,5-dihydro-furan-3-yl)-acetic acid
EINECS 228-663-3
cis-acotinic anyhydride
cis-Aconitic acid anhydride
3-Furanacetic acid, tetrahydro-2,5-dioxo-
propene-1,2,3-tricarboxylic acid-1,2-anhydride
cis-Aconitic anhydride
cis-Propene-1,2,3-tricarboxylic anhydride
Aconitic anhydride
3-Furanacetic acid,2,5-dihydro-2,5-dioxo

顺式乌头酸酐物理化学性质

[ 密度 ]:
1.5±0.1 g/cm3

[ 沸点 ]:
439.9±18.0 °C at 760 mmHg

[ 熔点 ]:
75-78 °C(lit.)

[ 分子式 ]:
C₆H₄O₅

[ 分子量 ]:
158.109

[ 闪点 ]:
194.6±14.7 °C

[ 精确质量 ]:
158.021530

[ PSA ]:
80.67000

[ LogP ]:
-1.61

[ 蒸汽压 ]:
0.0±2.3 mmHg at 25°C

[ 折射率 ]:
1.506

[ 储存条件 ]:
2-8°C

顺式乌头酸酐MSDS

顺式乌头酸酐安全信息

[ 符号 ]:

GHS05

[ 信号词 ]:
Danger

[ 危害声明 ]:
H314

[ 警示性声明 ]:
P280-P305 + P351 + P338-P310

[ 个人防护装备 ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
C

[ 风险声明 (欧洲) ]:
R34

[ 安全声明 (欧洲) ]:
S26-S36/37/39-S45

[ 危险品运输编码 ]:
UN 3261 8/PG 2

[ WGK德国 ]:
3

[ 包装等级 ]:
III

[ 危险类别 ]:
8

[ 海关编码 ]:
2918300090

顺式乌头酸酐合成路线

顺式乌头酸酐上下游产品

顺式乌头酸酐上游产品

顺式乌头酸酐下游产品

顺式乌头酸酐海关

[ 海关编码 ]: 2918300090

[ 中文概述 ]:
2918300090 其他含醛基或酮基不含其他含氧基羧酸（包括酸酐、酰卤化物、过氧化物和过氧酸及该税号的衍生物）. 增值税率:17.0% 退税率:9.0% 监管条件:无最惠国关税:6.5% 普通关税:30.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2918300090 other carboxylic acids with aldehyde or ketone function but without other oxygen function, their anhydrides, halides, peroxides, peroxyacids and their derivatives。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:6.5%。General tariff:30.0%

顺式乌头酸酐文献

Enhanced shRNA delivery and ABCG2 silencing by charge-reversible layered nanocarriers.

Small 11(8) , 952-62, (2015)

Polycationic vectors have been used to deliver short hairpin RNAs (shRNAs) to knock-down genes for cancer therapies, but their inefficiency in lysosomal escape and shRNA release causes their low gene ...

Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release.

Drug Deliv. 22 , 389-99, (2015)

The sustained release implants can be directly implanted in tumor site by surgery and are promising for cancer treatment.RGD-modified PEGylated polyamidoamine (PAMAM) dendrimer with doxorubicin (DOX) ...

Acid-responsive PEGylated doxorubicin prodrug nanoparticles for neuropilin-1 receptor-mediated targeted drug delivery.

Colloids Surf. B Biointerfaces 136 , 365-74, (2015)

Self-assembled prodrug nanoparticles have demonstrated great promise in cancer chemotherapy. In the present study, we developed a new kind of prodrug nanoparticles for targeted drug delivery. PEGylate...

更多文献